Michail A. Ovcharov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michail A. Ovcharov has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Alexander V. Afanasyev
Heart Valves Surgery Department, E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
2 shared publicationsAlexander V. Bogachev-Prokophiev
Heart Valves Surgery Department, E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
2 shared publicationsRavil M. Sharifulin
Heart Valves Surgery Department, E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
2 shared publicationsSergey O. Lavinykov
Heart Valves Surgery Department, E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
2 shared publicationsA. V. Afanasyev
Meshalkin National Medical Research Center
1 shared publication- Alexander Vladimirovich Bogachev-Prokophiev
Meshalkin National Medical Research Center
1 shared publication
Latest Publications
- 1 December 2021
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 30 (12) , 1949-1957
Rigid Ring Versus Flexible Band for Tricuspid Valve Repair in Patients Scheduled for Mitral Valve Surgery: A Prospective Randomised Study
- 1 December 2021
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 30 (12) , 1949-1957
Rigid Ring Versus Flexible Band for Tricuspid Valve Repair in Patients Scheduled for Mitral Valve Surgery: A Prospective Randomised Study
- 1 June 2021
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 30 (6) , 922-931
Surgical Atrial Fibrillation Ablation With and Without Left Atrium Reduction for Patients Scheduled for Mitral Valve Surgery: A Prospective Randomised Study
- 1 June 2021
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 30 (6) , 922-931
Surgical Atrial Fibrillation Ablation With and Without Left Atrium Reduction for Patients Scheduled for Mitral Valve Surgery: A Prospective Randomised Study
- Open Access
- 28 November 2018
- Published by Cardiology Research Institute in The Siberian Journal of Clinical and Experimental Medicine
- Vol. 33 (3) , 63-70
CONCOMITANT PROCEDURE OF ATRIAL FIBRILLATION ABLATION WITH AND WITHOUT LEFT ATRIOPLASTY DURING SURGICAL CORRECTION OF THE MITRAL VALVE DISEASE: PROSPECTIVE, RANDOMIZED TRIAL
Objective. Main objective of this prospective randomized study was to assess safety and efficiency of the combined approach for the left atrial ablation in combination with and without reduction left atrioplasty in patients with mitral valve disease.Material and Methods. The study was performed from September, 2014 to February, 2017. A total of 120 patients with mitral valve disease, permanent atrial fibrillation (AF), and left atriomegaly were enrolled in the study. Patients were randomized to two groups: group I comprised patients who received correction of mitral valve disease in combination with AF ablation and without reduction atrioplasty of the left atrium (MV+MAZE); group II (n=60) comprised patients with correction of mitral valve disease in combination with AF ablation and with reduction atrioplasty of the left atrium (MV+MAZE+AP). Patient characteristics did not differ between groups.Results. There were no significant differences between groups in the early mortality rates (2 patients in group I versus 5 patients in group II, p=0.64); bleeding rates (total 5 cases including 2 patients in group I and 3 patients in group II, p=0.34), and the rates of AF recurrence in the early postoperative period. Permanent pacemakers were implanted in 8 patients (13.3%) of group I and in 4 patients (6.7%) of group II. Total long-term mortality was 4 patients including 1 and 3 patients in group I and II, respectively, which did not significantly differed. The rates of one-year freedom from AF were 84.8 and 86.2% in group I and II, respectively. No new onsets of atrial fibrillation were observed for 36 months in both groups. The rates of freedom from thromboembolic events during the time of observation were 88.6% in group I and 96.5% in group II. Conclusion. The left atrial reduction concomitant with the left atrial ablation and correction of mitral valve disease is safe and effective procedure. However, this procedure did not impact the rates of long-term freedom from AF.
- 28 November 2018
- Published by Cardiology Research Institute in The Siberian Journal of Clinical and Experimental Medicine
- Vol. 33 (3) , 63-70
Open AccessCONCOMITANT PROCEDURE OF ATRIAL FIBRILLATION ABLATION WITH AND WITHOUT LEFT ATRIOPLASTY DURING SURGICAL CORRECTION OF THE MITRAL VALVE DISEASE: PROSPECTIVE, RANDOMIZED TRIAL
Objective. Main objective of this prospective randomized study was to assess safety and efficiency of the combined approach for the left atrial ablation in combination with and without reduction left atrioplasty in patients with mitral valve disease.Material and Methods. The study was performed from September, 2014 to February, 2017. A total of 120 patients with mitral valve disease, permanent atrial fibrillation (AF), and left atriomegaly were enrolled in the study. Patients were randomized to two groups: group I comprised patients who received correction of mitral valve disease in combination with AF ablation and without reduction atrioplasty of the left atrium (MV+MAZE); group II (n=60) comprised patients with correction of mitral valve disease in combination with AF ablation and with reduction atrioplasty of the left atrium (MV+MAZE+AP). Patient characteristics did not differ between groups.Results. There were no significant differences between groups in the early mortality rates (2 patients in group I versus 5 patients in group II, p=0.64); bleeding rates (total 5 cases including 2 patients in group I and 3 patients in group II, p=0.34), and the rates of AF recurrence in the early postoperative period. Permanent pacemakers were implanted in 8 patients (13.3%) of group I and in 4 patients (6.7%) of group II. Total long-term mortality was 4 patients including 1 and 3 patients in group I and II, respectively, which did not significantly differed. The rates of one-year freedom from AF were 84.8 and 86.2% in group I and II, respectively. No new onsets of atrial fibrillation were observed for 36 months in both groups. The rates of freedom from thromboembolic events during the time of observation were 88.6% in group I and 96.5% in group II. Conclusion. The left atrial reduction concomitant with the left atrial ablation and correction of mitral valve disease is safe and effective procedure. However, this procedure did not impact the rates of long-term freedom from AF.